DE69816608D1 - 1h-pyrazolo[3,4-d]pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen - Google Patents

1h-pyrazolo[3,4-d]pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen

Info

Publication number
DE69816608D1
DE69816608D1 DE69816608T DE69816608T DE69816608D1 DE 69816608 D1 DE69816608 D1 DE 69816608D1 DE 69816608 T DE69816608 T DE 69816608T DE 69816608 T DE69816608 T DE 69816608T DE 69816608 D1 DE69816608 D1 DE 69816608D1
Authority
DE
Germany
Prior art keywords
pct
pyrazolo
dione
pyrimidine
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69816608T
Other languages
English (en)
Other versions
DE69816608T2 (de
Inventor
David Cheshire
Martin Cooper
David Donald
Philip Thorne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69816608D1 publication Critical patent/DE69816608D1/de
Application granted granted Critical
Publication of DE69816608T2 publication Critical patent/DE69816608T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
DE69816608T 1997-04-15 1998-04-07 1h-pyrazolo[3,4-d]pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen Expired - Fee Related DE69816608T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9701398A SE9701398D0 (sv) 1997-04-15 1997-04-15 Novel compounds
SE9701398 1997-04-15
PCT/SE1998/000640 WO1998046606A1 (en) 1997-04-15 1998-04-07 Novel compounds

Publications (2)

Publication Number Publication Date
DE69816608D1 true DE69816608D1 (de) 2003-08-28
DE69816608T2 DE69816608T2 (de) 2004-04-15

Family

ID=20406576

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69816608T Expired - Fee Related DE69816608T2 (de) 1997-04-15 1998-04-07 1h-pyrazolo[3,4-d]pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen

Country Status (21)

Country Link
US (1) US6028074A (de)
EP (1) EP0975636B1 (de)
JP (1) JP2001520645A (de)
KR (1) KR20010006350A (de)
CN (1) CN1259951A (de)
AT (1) ATE245648T1 (de)
AU (1) AU733066B2 (de)
BR (1) BR9808540A (de)
CA (1) CA2286078A1 (de)
DE (1) DE69816608T2 (de)
EE (1) EE9900465A (de)
HU (1) HUP0002104A3 (de)
ID (1) ID22746A (de)
IL (1) IL132153A0 (de)
IS (1) IS5198A (de)
NO (1) NO995006D0 (de)
PL (1) PL336230A1 (de)
SE (1) SE9701398D0 (de)
SK (1) SK135699A3 (de)
TR (1) TR199902538T2 (de)
WO (1) WO1998046606A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2004527541A (ja) 2001-03-01 2004-09-09 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
ES2429132T3 (es) 2001-08-31 2013-11-13 The Rockefeller University Atividad de fosfodiesterasa y regulación de la señalización mediada por fosfodiesterasa 1-B en el cerebro
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
US9226885B2 (en) * 2005-05-24 2016-01-05 Allium Vitalis Incorporated Personal care and medicinal products incorporating bound organosulfur groups
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
CA2651519A1 (en) * 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
MX2010006208A (es) * 2007-12-06 2010-12-21 Intra Cellular Therapies Inc Compuestos organicos.
AU2008335811B2 (en) 2007-12-06 2012-05-17 Intra-Cellular Therapies, Inc. Organic compounds
US8536159B2 (en) 2008-12-06 2013-09-17 Intra-Cellular Therapies, Inc. Organic compounds
BRPI0922131A2 (pt) 2008-12-06 2015-08-18 Intracellular Therapies Inc Compostos orgânicos
JP5710492B2 (ja) 2008-12-06 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
KR20110098732A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP5813511B2 (ja) * 2008-12-06 2015-11-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
AP3280A (en) * 2009-03-23 2015-05-31 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as TRPA1 modulators
SG174398A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
BRPI1009372A2 (pt) 2009-03-23 2016-05-31 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica e respectivos usos
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
DK3127427T3 (da) 2009-05-29 2020-04-06 Novartis Ag Fremgangsmåder til administration af trombopoietinagonistforbindelser
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
EP2575817A4 (de) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc Organische verbindungen
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
EP2858999B1 (de) 2012-06-08 2017-05-10 Glenmark Pharmaceuticals S.A. Amide von 2-amino-2-arylthiazol-verbindungen und ihre salze
EP2956141A4 (de) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc Neuartige verwendungen
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
PL2970279T3 (pl) 2013-03-15 2021-05-31 Intra-Cellular Therapies, Inc. Związki organiczne
EP3091983B1 (de) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmazeutische zusammensetzungen enthaltend einen pde-1-hemmer und einen pde-2-hemmer
EP3157926B1 (de) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organische verbindungen
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CN107106563B (zh) 2014-09-17 2021-05-25 细胞内治疗公司 化合物和方法
BR112017012005B1 (pt) 2014-12-06 2023-04-04 Intra-Cellular Therapies, Inc Compostos orgânicos inibidores de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
EP3226870B1 (de) 2014-12-06 2019-09-25 Intra-Cellular Therapies, Inc. Organische verbindungen
EP3436083A4 (de) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Neuartige zusammensetzungen und verfahren
CN109311886B (zh) * 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982003626A1 (en) * 1981-04-22 1982-10-28 Gauri Kailash Kumar New derivatives of pyrazolo(3,4-d)pyrimidine,preparation method thereof and remedy containing them
US4603203A (en) * 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
EP0237289A3 (de) * 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo[3,4-d]pyrimidinderivate, ihre Herstellung und Verwendung
ATE175961T1 (de) * 1992-12-17 1999-02-15 Pfizer Pyrazole mit crf antagonistischer aktivität
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines

Also Published As

Publication number Publication date
US6028074A (en) 2000-02-22
PL336230A1 (en) 2000-06-19
JP2001520645A (ja) 2001-10-30
KR20010006350A (ko) 2001-01-26
NO995006L (no) 1999-10-14
EP0975636B1 (de) 2003-07-23
TR199902538T2 (xx) 2000-02-21
SK135699A3 (en) 2000-05-16
IL132153A0 (en) 2001-03-19
EP0975636A1 (de) 2000-02-02
HUP0002104A3 (en) 2002-03-28
NO995006D0 (no) 1999-10-14
BR9808540A (pt) 2000-05-23
ID22746A (id) 1999-12-09
EE9900465A (et) 2000-04-17
AU733066B2 (en) 2001-05-03
CN1259951A (zh) 2000-07-12
WO1998046606A1 (en) 1998-10-22
CA2286078A1 (en) 1998-10-22
SE9701398D0 (sv) 1997-04-15
AU7090998A (en) 1998-11-11
HUP0002104A2 (hu) 2001-01-29
ATE245648T1 (de) 2003-08-15
IS5198A (is) 1999-09-27
DE69816608T2 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
DE69816608D1 (de) 1h-pyrazolo[3,4-d]pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
IS5082A (is) Pýrróló[3,4-D]pýrimídínon-afleiður og notkun þeirra sem lyfja
EE200000318A (et) Uudsed ühendid
SE9702772D0 (sv) Novel compounds
SE9702001D0 (sv) Novel compounds
BR9609617B1 (pt) derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
PT828728E (pt) Di-hidrobenzofuranos de fenilo
ATE251908T1 (de) Zusammensetzung zur behandlung sexueller funktionsstörungen die phosphodiesterase-5 inhibitoren enthaltend
CY2462B1 (en) Cyclohexyl dihydrobenzofuranes.
CA2046755A1 (en) /2r/-2-[di/2-propyl/phosphonylmethoxy]-3-p-toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use
HUP0400345A2 (hu) Vírusellenes aktivitású foszfono-pirimidin-származékok
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee